Characterization and treatment outcomes of rituximab therapy in super-responders and rituximab-refractory pemphigus patients: A single-center retrospective study
Published: 5 December 2025| Version 1 | DOI: 10.17632/nd6t3ptgk7.1
Contributors:
Zhili Wu, Jiefeng Jiang, Keyun Duan, Guomin Li, Feng Guo, Jiao Zhang, Ruzeng XueDescription
Supplementary Table 1 summarizes the baseline demographic and clinical characteristics of patients categorized into three response groups receiving rituximab. Supplementary Table 2 presents the univariable logistic regression analyses evaluating patient characteristics associated with super-responders compared with non–super-responders. Supplementary Table 3 contains the univariable logistic regression results identifying factors associated with rituximab-refractory pemphigus in comparison to non–refractory patients.
Files
Institutions
- Southern Medical University
Categories
Biologic Agent, Pemphigus